Organization · Private Equity
Kiniciti
Kiniciti is a buy-and-build platform focused on advancing cell and gene therapy through strategic investments in enabling technologies and services. Based in the U.S., it partners with companies that enhance the development and delivery of these therapies.
Overview
What Kiniciti does
What Kiniciti is
Kiniciti is a buy-and-build platform focused on advancing cell and gene therapy through strategic investments in enabling technologies and services. Based in the U.S., it partners with companies that enhance the development and delivery of these therapies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- April 25, 2026
Official channels
Find Kiniciti elsewhere
Open the official website or a supported primary organization account.
Capability profile
Kiniciti as a funder
Investment thesis
Kiniciti focuses on advancing cell and gene therapy through strategic partnerships and investments in non-therapeutic enablers, including cell engineering and gene-editing technologies.
Focus narrative
Kiniciti invests in opportunities related to cell sources, enabling technology platforms, process development, and patient delivery solutions. The organization seeks to partner with entities that can fulfill the promise of breakthrough treatments while reducing costs to ensure affordable access for patients.
Value beyond capital
Kiniciti provides strategic support to its portfolio companies by leveraging its expertise in cell and gene therapy, facilitating partnerships, and enhancing operational capabilities to drive growth and innovation.
Terms and economics
- Typical check
- $60,000,000–$250,000,000
Focus and fit
- Stages
- Growth Equity
- Regions
- North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 2
Portfolio context
Current operating companies under Kiniciti include: Cellistic: Develops iPSC-based manufacturing technologies for cell therapies. Ncardia: Collaborates with clients to advance drug discovery programs for cardiovascular and neurological diseases using human iPSC products and services.
Common questions
What to know about Kiniciti
Upseed classifies Kiniciti under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 25, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.